Anti-Human CD253 (TRAIL) PE
Additional RIK-2 Formats
Cat.No. | Format | Starting From |
---|---|---|
25611-25 | SAFIRE Purified | $ 145.00 |
25611-60 | PE | $ 220.00 |
Catalog Number : 25611-60
description
The RIK-2 monoclonal antibody recognizes human CD253, otherwise known as the TNF-related apoptosis inducing ligand (TRAIL) or tumor necrosis factor (ligand) superfamily member 10 (TNFSF10). TRAIL is a cytotoxic protein, which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apoptosis is achieved through binding to two death-signaling receptors, DR4 and DR5. These receptors belong to the TNFR superfamily of transmembrane proteins, and contain a cytoplasmic "death domain", which activates the cell's apoptotic machinery. The RIK-2 antibody is reported to block cellular apoptosis induced by TRAIL.
Additional Information
Clone: | RIK-2 |
Format: | PE |
Applications: | FC |
Reactivity: | Human |
Isotype: | Mouse IgG1, kappa |
Research Interest: | Apoptosis |
---|---|
Application: | FC |
Clone: | RIK-2 |
Preparation: | The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product. |
Formulation: | Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2. |
References: | Kayagaki, N., Yamaguchi, N., Nakayama, M., Kawasaki, A., Akiba, H., Okumura, K., & Yagita, H. (1999). Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. The Journal of Immunology, 162(5), 2639-2647. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996). Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. Journal of Biological Chemistry,271(22), 12687-12690. Kaplan, M. J., Ray, D., Mo, R. R., Yung, R. L., & Richardson, B. C. (2000). TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages. The Journal of Immunology, 164(6), 2897-2904. |